Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
COYA Coya Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: COYA
Price (delayed)
$5.71
Market cap
$95.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.07
Enterprise value
$59.97M
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities,
Highlights
COYA's revenue is down by 40% YoY but it is up by 3.7% from the previous quarter
The gross profit has declined by 40% year-on-year but it has increased by 3.7% since the previous quarter
COYA's net income has shrunk by 66% YoY and by 15% QoQ
The EPS has declined by 26% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of COYA
Market
Valuations
Earnings
Shares outstanding
16.72M
Market cap
$95.5M
Enterprise value
$59.97M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.86
Price to sales (P/S)
25.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.27
Revenue
$3.69M
Gross profit
$3.69M
Operating income
-$19.44M
Net income
-$17.14M
EBIT
-$17.86M
EBITDA
-$17.83M
Free cash flow
-$15.26M
Per share
Balance sheet
Liquidity
EPS
-$1.07
EPS diluted
-$1.07
Free cash flow per share
-$0.91
Book value per share
$2
Revenue per share
$0.22
TBVPS
$2.3
Total assets
$38.4M
Total liabilities
$5.04M
Debt
$0
Equity
$33.37M
Working capital
$34.03M
Debt to equity
0
Current ratio
8.84
Quick ratio
8.18
Net debt/EBITDA
1.99
Margins
Efficiency
Dividend
EBITDA margin
-483.8%
Gross margin
100%
Net margin
-465%
Operating margin
-527.6%
Return on assets
-43.3%
Return on equity
-48.9%
Return on invested capital
-2,939.6%
Return on capital employed
-52.4%
Return on sales
-484.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COYA stock price
How has the Coya Therapeutics stock price performed over time
Intraday
1.06%
1 week
1.96%
1 month
-10.36%
1 year
-23.36%
YTD
-0.35%
QTD
-11.75%
Financial performance
How have Coya Therapeutics's revenue and profit performed over time
Revenue
$3.69M
Gross profit
$3.69M
Operating income
-$19.44M
Net income
-$17.14M
Gross margin
100%
Net margin
-465%
Coya Therapeutics's net margin has plunged by 177% YoY and by 11% from the previous quarter
Coya Therapeutics's operating income has plunged by 85% YoY and by 13% from the previous quarter
COYA's net income has shrunk by 66% YoY and by 15% QoQ
COYA's revenue is down by 40% YoY but it is up by 3.7% from the previous quarter
Price vs fundamentals
How does COYA's price correlate with its fundamentals
Growth
What is Coya Therapeutics's growth rate over time
Valuation
What is Coya Therapeutics stock price valuation
P/E
N/A
P/B
2.86
P/S
25.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.27
The EPS has declined by 26% year-on-year and by 9% since the previous quarter
The company's equity fell by 16% QoQ but it rose by 3% YoY
The P/B is 2.1% above the last 4 quarters average of 2.8
COYA's P/S is 41% above its last 4 quarters average of 18.4
COYA's revenue is down by 40% YoY but it is up by 3.7% from the previous quarter
Efficiency
How efficient is Coya Therapeutics business performance
COYA's return on invested capital has surged by 99% year-on-year and by 54% since the previous quarter
Coya Therapeutics's return on equity has decreased by 15% QoQ and by 8% YoY
The ROA has contracted by 14% from the previous quarter and by 10% YoY
The return on sales has declined by 10% since the previous quarter
Dividends
What is COYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COYA.
Financial health
How did Coya Therapeutics financials performed over time
COYA's current ratio is down by 24% since the previous quarter but it is up by 2.3% year-on-year
The company's quick ratio fell by 18% QoQ
Coya Therapeutics's debt is 100% less than its equity
The company's equity fell by 16% QoQ but it rose by 3% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.